BlackRock
ESG backlash: Turbulent tailwinds
The strong momentum behind sustainable and responsible investment policies globally has begun to ruffle feathers in the US. Asian private equity should recognise this as a relevant warning
BlackRock, New Zealand launch $1.2b climate fund
BlackRock will manage a climate fund launched alongside the New Zealand government with a target of NZD 2bn (USD 1.2bn). It will focus on renewable energy.
Carlyle-backed Adicon trades up after $52m Hong Kong IPO
Adicon Holdings, a China-based independent clinical laboratory (ICL) services provider backed by The Carlyle Group, gained 12% on debut following a HKD 408.9m (USD 52.2m) Hong Kong IPO.
BlackRock hires Campbell Lutyens' Asia head
BlackRock has recruited George Maltezos, formerly head of Asia Pacific at placement agent Campbell Lutyens, to lead alternatives distribution in the region.
Tread more cautiously in PE-infra overlap – AVCJ Forum
Investors are increasingly challenged to reconcile a vanishing divide between some infrastructure and PE strategies, the AVCJ Private Equity & Venture Forum heard.
Q&A: BlackRock’s Michael Dennis
Michael Dennis, managing director and head of alternatives strategy and capital markets for Asia Pacific at BlackRock, on co-investment, customisation, and what Asian investors want from alternatives
Investors endorse 'long Chinese' thesis - AVCJ webinar
The shift from “long China” to “long Chinese,” which has gained traction as a soundbite as investors look to back local entrepreneurs in overseas markets, was highlighted once again during AVCJ’s China Private Markets Outlook webinar.
Taking PE in-house: Less limited partners
Institutional investors continue to pursue more active roles in private equity, even as a souring macro backdrop makes the game harder to play. Talent is always the key variable
Saudi Arabia's Sidra targets Asia, teams up with BlackRock
Sidra Capital, a Saudi Arabia-based alternative asset manager, has teamed up with BlackRock to offer shariah-compliant private equity opportunities in Asia Pacific.
BlackRock leads $300m investment in Indonesia's Traveloka
BlackRock has led a USD 300m investment in Indonesia’s Traveloka via a credit fund as expectations mount for an IPO by the travel platform.
LPs emphasize differentiation in China venture capital
LPs want to back Chinese venture capital firms that are differentiated from their peers, although there remains an element of discomfort with efforts to achieve this through increasingly popular China-plus strategies.
Mithril, BlackRock invest $110m in Singapore’s GreyOrange
Mithril Capital, a VC firm launched by PayPal co-founder Peter Thiel, and BlackRock have provided USD 110m in growth funding to Singapore and US-based robotics player GreyOrange.
India's Byju's raises $800m at $22b valuation
Indian education platform Byju’s has raised USD 800m at an estimated valuation of USD 22bn, with the company’s founder Byju Raveendran providing USD 400m.
PE-backed Abbisko trades up after $225m Hong Kong IPO
China-based oncology drug developer Abbisko Therapeutics gained nearly 10% on its Hong Kong trading debut following a HK$1.75 billion ($225 million) IPO.
Australia's SiteMinder secures $73m pre-IPO round
Australia-based hotel booking platform SiteMinder has raised a A$100 million ($73 million) pre-IPO round led by BlackRock and AustralianSuper.
India's Pine Labs raises $315m at $3.5b valuation
Indian financial technology provider Pine Labs has raised a $315 million round featuring BlackRock at a post-money valuation of about $3.5 billion.
Deal focus: NiKang pursues hard-to-drug targets
With big pharma scaling back early-stage discovery, CBC Group is keen to incubate biotech start-ups developing drugs from scratch. NiKang Therapeutics is the first to secure wider investor attention
Vision Fund, BlackRock lead Series D for Singapore's Trax
Trax, a Singapore-headquartered start-up that uses computer vision technology to help retailers link sales to in-store and on-shelf positioning, has secured $640 million in Series E funding led by SoftBank Vision Fund 2 and BlackRock.
China direct lending: Creative credit
A combination of improved collateral, rising yields and robust demand is drawing investors to China’s direct lending space. Opportunities abound, but local execution remains critical
China's Connect Biopharma gains 8% on debut after $191m US IPO
Connect Biopharma, a China-headquartered drug developer specializing in treatments for T cell-driven inflammatory diseases, gained 8.8% on debut following a $191.3 million US IPO.
Shariah investors in PE: Tailored exposure
Employees Provident Fund’s $600 million shariah-compliant co-investment mandate suggests increasing institutional appetite for Islamic finance solutions in private equity. Is the industry ready?